Investor Presentaiton slide image

Investor Presentaiton

Number of detectable tumor alterations drives sensitivity Genomic analysis MD MD ID GUARDANTâ„¢ Epigenomic analysis |||| Tissue Informed Assays Up to 50 Tumor Alterations Smart Liquid Biopsy INVESTOR 20 DAY 23 | | |ID >1,000 Tumor Alterations 29 29
View entire presentation